Researchers at the University of Edinburgh successfully reversed the symptoms of Rett Syndrome in a genetic mouse model, restoring normal brain function and mobility. The study's findings, published in Science Express, have significant implications for the treatment and potential cure of autism spectrum disorders.
Researchers have discovered that mice with a mutated version of the MECP2 protein exhibit high levels of corticosterone, a stress hormone linked to anxiety and other symptoms of Rett Syndrome. The study suggests that blocking receptors for corticotropin-releasing hormone may reduce anxiety in individuals with RTT.
Researchers discovered that phosphorylation of MeCP2 at S421 increases transcription of genes required for experience-dependent brain maturation, including BDNF. This study reveals a complex regulatory loop between BDNF and neuronal activity in regulating MeCP2 function.
Researchers have found that mutations in MECP2 lead to overproduction of Uqcrc1 protein in mitochondria, resulting in abnormal energy production and potentially causing Rett syndrome symptoms. The study provides a genetic link between MECP2 and mitochondrial function, offering new insights into the disorder.
Researchers have found that brain-derived neurotrophic factor (BDNF) can alleviate disease symptoms in a mouse model of Rett Syndrome. Increasing BDNF levels slowed down disease progression and improved mouse survival, suggesting potential therapeutic applications for the disorder.
Researchers discover that disturbances in norepinephrine levels lead to breathing problems in RTT mice. Increasing norepinephrine helps normalize breathing patterns, suggesting a potential therapeutic approach for the disorder.
The MECP2 gene, responsible for Rett syndrome, plays a multifunctional role in RNA processing, including transcriptional repression and splicing regulation. This discovery opens new avenues for understanding the disease and developing targeted therapies.
Researchers have made a crucial breakthrough in understanding Rett Syndrome by identifying the specific genetic targets involved in the disease. The discovery of an A-T stretch required for MeCP2 binding provides a key clue to finding new target genes.
A mouse model of Rett Syndrome displays reduced cortical activity, suggesting a primary cellular defect. The study found that the excitatory-inhibitory balance in the cortex is shifted towards inhibition, which may underlie cognitive, motor, and social symptoms in RTT.
Researchers found that MECP2 target gene DLX5 is overexpressed in RTT patients due to loss of silent chromatin looping and impaired imprinting. This misregulation leads to increased expression of GABA, a neurotransmitter essential for brain function.
Rett Syndrome researchers successfully introduced the 'Rett protein' into post-mitotic neurons, reversing symptoms in mice. This breakthrough could pave the way for new treatments and potentially even cures for Rett Syndrome, a devastating neurological disorder primarily affecting girls.
Researchers have identified a novel form of the Rett syndrome protein, which is more abundant in human brain than previously thought. This discovery may provide insights into potential functional differences between the two proteins and help identify mutations in exon 1.
A new form of the MeCP2 protein has been discovered, which may be more important in causing Rett Syndrome. The protein is found to be more abundant in the brain and its function must be understood to relate it to the disease symptoms.
A new study reveals that MeCP2, a protein implicated in Rett Syndrome, regulates brain-derived neurotrophic factor (BDNF), leading to symptoms. Researchers found that MeCP2 controls BDNF's 'off' state, but also enables its activation through temporary detachment.